Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of ($0.04), $0.05 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $45.27 million versus the consensus estimate of $37 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.